ArticleCirculation2022
Impaired AMP-Activated Protein Kinase Signaling in Heart Failure With Preserved Ejection Fraction-Associated Atrial Fibrillation.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 37 citations in OpenAlex.
- Understanding the Diseased Atria.Physiology (Bethesda, Md.) · 2026Review
- The clinical pathophysiology of atrial fibrillation: outstanding questions from bedside to bench and back.Physiological reviews · 2026Review
- Selective loss of Cx40 and conduction abnormalities underlie enhanced atrial fibrillation susceptibility in a HFpEF model in male mice.Physiological reports · 2026Article
- Mitochondrial dysfunction drives ZBP1-mediated PANoptosis to increase the susceptibility of heart failure with preserved ejection fraction-associated atrial fibrillation.Journal of advanced research · 2026Article
- Cellular basis of HFpEF: contributions of abnormal lipids.Frontiers in cardiovascular medicine · 2026Review
- Trigonelline Improves Metabolism and Cardiac Function of HFpEF Mice Via Gut Microbiome Alterations-Mediated AMPK Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cyclophilin B deficiency enhances myocardial energy synthesis and protects against heart failure in preclinical models.BMC medicine · 2025Article
- Succinate-GPR91 signaling promotes cardiomyocyte metabolic reprogramming and NADCardiovascular diabetology · 2025Article
- Metabolic Remodeling and Mitochondrial Stress in Atrial Fibrillation: Mechanisms and Translational Targets.Reviews in cardiovascular medicine · 2025Review
- What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?JACC. Basic to translational science · 2025Review
- Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.Nature reviews. Cardiology · 2025Review
- Succinate-GPR91 signaling promotes cardiomyocyte metabolic reprogramming and NADResearch square · 2025Article
- Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats.Chinese medicine · 2025Article
- PFKM-Driven Lactate Overproduction Promotes Atrial Fibrillation via Triggering Cardiac Fibroblasts Histone Lactylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Fibroblast-Restricted Inflammasome Activation Promotes Atrial Fibrillation and Heart Failure With Diastolic Dysfunction.JACC. Basic to translational science · 2025Article
- The Interplay Between Pulmonary Hypertension and Atrial Fibrillation: A Comprehensive Overview.Cells · 2025Review
- Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos.Circulation research · 2025Review
- Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts.Journal of clinical medicine · 2025Review
- Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice.Nature communications · 2025Article
- AMP-Activated Protein Kinase Activators as Therapeutic Targets To Treat Heart Failure and Diseases That Can Benefit from Improved Muscular Performance.ACS medicinal chemistry letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 4 countries.
Dan TongDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-3551-2861
Gabriele G SchiattarellaCenter for Cardiovascular Research (CCR), Department of Cardiology, Charité - Universitätsmedizin Berlin, Germany (G.G.S.).ORCID 0000-0002-7582-7171
Nan JiangDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.
Daniel DaouDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-9912-6855
Yuxuan LuoDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.
Mark S LinkDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0001-5277-9296
Sergio LavanderoAdvanced Center for Chronic Diseases (ACCDiS) & Center for Molecular Studies of the Cell (CEMC), Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine, University of Chile, Santiago (S.L.).ORCID 0000-0003-4258-1483
Thomas G GilletteDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-7617-3544
Joseph A HillDepartment of Internal Medicine (Cardiology) (D.T., N.J., D.D., Y.L., M.L., S.L., J.A.H.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-5379-1614
Southwestern Medical Center · USAdvanced Center for Chronic Diseases · CLMax Delbrück Center · DE
Funding
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PHILIPP E SCHERER · 2022 to 2026
$7.4MCardiomyocyte bromodomain protein 4 (BRD4) in physiology and diseaseR01HL147933 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2020 to 2023
$2.5MMolecular Mechanisms of HFpEF-associated Atrial FibrillationR01HL155765 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GILLETTE, THOMAS G, HILL, JOSEPH A · 2021 to 2024
$1.6MMechanisms of obesity-dependent alterations in cardiomyocyte metabolismR01HL128215 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2017 to 2020
$1.6MFoxO-dependent Control of Cardiovascular RemodelingR01HL126012 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2016 to 2019
$1.6MRodent Ultrasound Imaging SystemS10RR023729 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2009 to 2009
$290kProtein Acetylation-dependent Control of Metabolic Remodeling in Heart Failure with Preserved Ejection Fraction (HFpEF)F32HL142244 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI TONG, DAN · 2018 to 2019
$90kNCRR NIH HHS S10 RR023729NHLBI NIH HHS F32 HL142244NHLBI NIH HHS R01 HL126012NHLBI NIH HHS R01 HL128215NHLBI NIH HHS R01 HL147933NHLBI NIH HHS R01 HL155765NIDDK NIH HHS P30 DK127984
Abstract
PubMed holds no abstract for this paper.
Indexed as
Atrial FibrillationHeart FailureAMP-Activated Protein KinasesHumansPrognosisStroke VolumeVentricular Function, LeftAMP-Activated Protein Kinasesatrial fibrillationheart failure, diastolic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.